IHE:NYE-iShares U.S. Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 63.78

Change

-1.34 (-2.06)%

Market Cap

N/A

Volume

0.13M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-21 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-3.12 (-2.32%)

USD 35.08B
FHLC Fidelity® MSCI Health Care In..

-1.56 (-2.45%)

USD 2.50B
FXH First Trust Health Care AlphaD..

-2.83 (-2.73%)

USD 0.90B
XHE SPDR® S&P Health Care Equipme..

-2.55 (-3.06%)

USD 0.16B
IDNA iShares Genomics Immunology an..

-0.39 (-1.91%)

USD 0.10B
XHS SPDR® S&P Health Care Service..

-2.77 (-2.75%)

USD 0.09B
SBIO ALPS Medical Breakthroughs ETF

-0.78 (-2.66%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.83 (-3.00%)

USD 0.04B
BBP Virtus LifeSci Biotech Product..

-1.43 (-2.50%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.64 (-3.42%)

USD 0.01B

ETFs Containing IHE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -2.95% 81% B- 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.95% 81% B- 37% F
Trailing 12 Months  
Capital Gain -4.29% 71% C- 34% F
Dividend Return 0.98% 88% B+ 21% F
Total Return -3.31% 71% C- 29% F
Trailing 5 Years  
Capital Gain 24.53% 67% D+ 46% F
Dividend Return 8.86% 95% A 19% F
Total Return 33.39% 71% C- 38% F
Average Annual (5 Year Horizon)  
Capital Gain 2.70% 67% D+ 48% F
Dividend Return 4.08% 67% D+ 44% F
Total Return 1.38% 100% F 33% F
Risk Return Profile  
Volatility (Standard Deviation) 14.23% 62% D 66% D+
Risk Adjusted Return 28.68% 67% D+ 46% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike